Material Detail

Biogen offered a window into what's holding up Aduhelm. Investors didn't like what they saw.

Biogen offered a window into what's holding up Aduhelm. Investors didn't like what they saw.

At Morgan Stanley’s healthcare conference, executives detailed how the launch of their Alzheimer’s drug has been slower than expected, due in large part to lingering questions about clinical trial data and insurance coverage.

Quality

  • User Rating
  • Comments
  • Learning Exercises
  • Bookmark Collection (1) Bookmark Collections
  • Course ePortfolios
  • Accessibility Info

More about this material

Browse...

Disciplines with similar materials as Biogen offered a window into what's holding up Aduhelm. Investors didn't like what they saw.

Comments

Log in to participate in the discussions or sign up if you are not already a MERLOT member.